A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinotecan in patients with advanced hepatocellular carcinoma and who relapsed after a first line therapy with sorafenib.
Phase of Trial: Phase I/II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Masitinib (Primary) ; Etoposide; Irinotecan
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors AB Science
- 21 Sep 2017 This trial has been suspended in Slovakia.
- 10 Jun 2017 Biomarkers information updated
- 02 Jul 2015 In July 2015, an interim analysis was conducted by the DSMB; it was recommended that the study continue as planned, according to an AB Science media release.